scholarly journals Cardiotoxic effects induced by the use of antimetabolites in the chemotherapy of oncological diseases

2021 ◽  
Vol 12 (3) ◽  
pp. 177-181
Author(s):  
Alina A. Aliab'eva ◽  
Galina S. Mal
Keyword(s):  
Side Effects ◽  
Cardiovascular System ◽  
Cancer Patients ◽  
Clinical Manifestations ◽  
Vascular Pathology ◽  
Malignant Neoplasms ◽  
Heart Damage ◽  
Negative Effect ◽  
Modern Medical Practice ◽  
Search For Information

In modern medical practice, the treatment of cancer is one of the most pressing issues. Many of the drugs used in the treatment of cancer have a toxic effect on the cardiovascular system of patients. The main clinical manifestations of cardiotoxicity are ischemic heart damage, rhythm disturbances, thrombosis, angina, asymptomatic changes in the electrocardiogram, and others. Side effects can develop both during the treatment period and months after the end of the course of chemotherapy. This is especially important for patients with concomitant cardiac or vascular pathology, since the severity of developing side effects can lead to disability or death of cancer survivors. The article discusses the data on the frequency of detection of the negative effect of pyrimidine, purine and folic acid antagonists on the cardiovascular system of cancer patients, the mechanisms of cardiotoxic effects of drugs in such patients, the possibilities of preventing heart damage and correcting for already developed lesions. The aim of this work is to collect, compare and systematize the available disparate data on the cardiotoxic effects of antitumor drugs of the antimetabolite group. An important condition for saving and preserving the quality of life of cancer patients is the identification of cardiovascular pathologies at the stage of preparation for chemotherapy, which can be facilitated by the active cooperation of oncologists and cardiologists. The search for information was carried out on the bases of scientific medical publications (eLibrary.ru, PubMed) taking into account the clinical recommendations for the treatment of malignant neoplasms.

Using Naïve Bayes Algorithm to Estimate the Response to Drug in Lung Cancer Patients

2019 ◽  
Vol 21 (10) ◽  
pp. 734-748 ◽  
Author(s):  
Baoling Guo ◽  
Qiuxiang Zheng
Keyword(s):  
Lung Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Drug Response ◽  
Treatment Options ◽  
Clinical Manifestations ◽  
Treatment Strategies ◽  
Cancer Resistance ◽  
Lung Cancer Patients ◽  
Bayes Algorithm

Aim and Objective: Lung cancer is a highly heterogeneous cancer, due to the significant differences in molecular levels, resulting in different clinical manifestations of lung cancer patients there is a big difference. Including disease characterization, drug response, the risk of recurrence, survival, etc. Method: Clinical patients with lung cancer do not have yet particularly effective treatment options, while patients with lung cancer resistance not only delayed the treatment cycle but also caused strong side effects. Therefore, if we can sum up the abnormalities of functional level from the molecular level, we can scientifically and effectively evaluate the patients' sensitivity to treatment and make the personalized treatment strategies to avoid the side effects caused by over-treatment and improve the prognosis. Result & Conclusion: According to the different sensitivities of lung cancer patients to drug response, this study screened out genes that were significantly associated with drug resistance. The bayes model was used to assess patient resistance.

scholarly journals LABORATORY CONTROL OF ANTICOAGULANT PROPHYLAXIS IN PREGNANT WOMEN WITH CARDIOVASCULAR DISEASES

World Science ◽  
2021 ◽  
Author(s):  
V. Medved ◽  
T. Savka
Keyword(s):  
Heart Disease ◽  
Side Effects ◽  
Pregnant Women ◽  
Cardiovascular System ◽  
Laboratory Research ◽  
Primary Hemostasis ◽  
Different Types ◽  
Mechanisms Of Formation ◽  
Negative Effect ◽  
Anticoagulant Prophylaxis

This article examines the effect of anticoagulant prophylaxis on pregnancy, childbirth and the postpartum period in women with heart disease. Тhe main mechanisms of formation of side effects from anticoagulant prophylaxis in pregnant women with diseases of the cardiovascular system were studied by means of laboratory research methods,. Have been studied the effects and interaction of different types of anticoagulant prophylaxis and aspirin prophylaxis on primary hemostasis. An algorithm for diagnosing the negative effect of anticoagulants on platelets has been developed. The study examines the possibility of drug correction of the development of side effects from anticoagulant thromboprophylaxis for women with diseases of the cardiovascular system.

scholarly journals FEATURES OF DENTAL STATUS IN PATIENTS WITH CANCER

2019 ◽  
Vol 15 (1) ◽  
pp. 63-67 ◽  
Author(s):  
Ольга Успенская ◽  
Ol'ga Uspenskaya ◽  
Ирина Фадеева ◽  
Irina Fadeeva
Keyword(s):  
Oral Cavity ◽  
Cancer Patients ◽  
Mucous Membrane ◽  
Clinical Manifestations ◽  
The Body ◽  
Dental Status ◽  
Malignant Neoplasms ◽  
Patients With Cancer ◽  
Periodontal Tissues ◽  
Dental Diseases

Subject. In the modern world, the prevalence of cancer is growing every year, in this regard, this pathology is one of the most pressing problems in medicine. There is no doubt that malignant neoplasms have a complex interaction with the body. The General mechanisms of occurrence and progression of the tumor process are intensively studied, and to date, a huge amount of material on molecular and clinical Oncology has been accumulated, it is used in related disciplines. The most important sections of dentistry are the diagnosis and treatment of diseases of the mucous membrane. Often, clinical manifestations in the oral cavity are one of the first symptoms indicating a General somatic disease. This article covers the study of the dental status of patients with different localizations of cancer. Objective ― to study the incidence of dental diseases of patients with cancer. Methodology. To conduct a study medical examination of patients with different localizations of cancer was held to determine dental: the definition of DMF-Index, PMA-index, Parodontal Index, and the condition of the mucous membrane of the oral cavity and periodontal tissues. Cancer patients receiving chemotherapy and radiation therapy, patients who refused to participate in the survey were excluded from the survey. Results. The study included 526 patients. The predominance of certain types of dental diseases among patients with a particular cancer pathology was revealed. Conclusions. Our study showed that all patients had decompensated forms of caries. The most common dental diseases combined with cancer are hyperplasia filiform papillae (K14.3), the "geographic" language (K14.1). Periodontal disease occurred in 69,5 % of cases among cancer patients.

scholarly journals CONDITION OF BONE TISSUE IN PREGNANT WOMEN WITH DISEASES OF THE CARDIOVASCULAR SYSTEM ON THE BACKGROUND OF ANTICOAGULANT PREVENTION

2021 ◽  
Author(s):  
V. Medved ◽  
T. Savka
Keyword(s):  
Heart Disease ◽  
Side Effects ◽  
Pregnant Women ◽  
Cardiovascular System ◽  
Bone Metabolism ◽  
Clinical Manifestations ◽  
Skeletal System ◽  
Sonographic Examination ◽  
Anticoagulant Prophylaxis ◽  
The Relationship

The article presents data on the development of side effects from anticoagulant prophylaxis in pregnant women with diseases of the cardiovascular system. In particular, the anticoagulant effects on the skeletal system. Were studied the features of sonographic examination in this category of patients. The level of the main biomarkers of osteosynthesis and osteoresorption during pregnancy was studied. Were analyzed the influence of anticoagulants on the level of biomarkers of bone metabolism. Has been studied the relationship between densitometry data and calcitonin levels in pregnant women. The main aspects of the formation of osteopenic syndrome and osteoporosis in pregnant women with heart disease are considered. Has been studied the relationship between the clinical manifestations of osteopenic syndrome and the level of biomarkers of bone metabolism. Proposed the drug correction of the development of side effects due to anticoagulant thromboprophylaxis.

scholarly journals AB1074 FEATURES OF COMBINED USE OF BIOMARKERS AND VISUALIZATION METHODS FOR DIAGNOSIS OF HEART DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1826.1-1826
Author(s):  
N. Aleksandrova ◽  
V. Aleksandrov ◽  
L. Shilova ◽  
A. Aleksandrov ◽  
I. Zborovskaya
Keyword(s):  
Rheumatoid Arthritis ◽  
Heart Disease ◽  
Cardiovascular System ◽  
Inflammatory Process ◽  
Imaging Techniques ◽  
Elisa Test ◽  
Vascular Pathology ◽  
Reactive Oxygen Intermediate ◽  
Heart Damage ◽  
Mitral Prolapse

Background:In rheumatoid arthritis (RA), the endocardium is involved in the inflammatory process, which is caused by immunopathogenetic mechanisms involving CD4 +, T-cells and proinflammatory macrophages. Minor changes in the cardiovascular system can be successfully detected by ultrasound in patients with RA.Objectives:to improve the quality of non-invasive diagnostics of heart disease in patients with RA.Methods:57 patients with RA were under observation: 7 men and 50 women aged from 26 to 70 years; mean age 50.45 ± 10.12 years; activity (according to DAS28) was low for 3.5%, medium for 86%, and high for 10.5%. Immunological examination included determination of serum IgM-RF, CRP, antibodies to cyclic citrulline peptide (anti-CCP), antibodies to modified vimentin (anti-MCV), antibodies to antigen RA33, levels of angiopoietin-like proteins 3 (ANGPTL3) and 4 (ANGPTL4) types (classical ELISA test), as well as the detection of IgG antibodies to 5’-nucleotidase (5’-NT) and xanthine oxidase (XO) (modified ELISA test). Data from ultrasound, magnetic resonance (MRT) and computer (CT) tomography were used in assessing the state of the heart structures.Results:The pathology of cardiovascular system was diagnosed in 28 (49.1%) patients with RA. Signs of the heart damage were noted in 33.3% of cases (pericarditis and valvular heart disease were most often detected). In groups of patients with RA with elevated levels of antibodies to 5’-NT and XO (compared with RA patients with normal parameters), there was a significantly more frequent heart damage (for antibodies to 5’-NT: χ2= 3.8, p = 0.047; for antibodies to XO: χ2= 3.92, p = 0.041). It was discovered that in all patients with an increased level of antibodies to XO, one of the lesions of the heart valvular apparatus of varying severity was noted. According to ultrasound data (usually confirmed by CT and / or MRT), signs of valvular dysfunction were found in 21 (36.8%) patients with RA. The high frequency of mitral prolapse (28.6%) may be associated with the presence of a chronic inflammatory process that is able to accelerate the development of atherosclerosis and heart disease in RA patients. A tendency to an increase in the prevalence of mitral prolapse in patients with a longer duration of the disease (p = 0.062) and with high levels of serum ANGPTL4 (p = 0.058) was found.One of the main factors leading to the development of vascular pathology in RA is the accumulation of reactive oxygen intermediate. Antibodies to XO can affect the biochemical activity of the enzyme in the serum of patients with RA, stimulating the increased formation of O-form XO, which has a pronounced prooxidant effect (especially to lipids). ANGPTL4, acting as a potent inhibitor of endothelial lipoprotein lipase, can suppress the release of non-esterified fatty acids and their transfer to the heart muscle.Conclusion:To identify subclinical signs of involvement of cardiovascular system in the pathological process in the early asymptomatic stages of RA, it is advisable to use imaging techniques in combination with immunological markers of heart damage, which can be especially useful for screening, diagnostic evaluation and determining cardiovascular risk.Disclosure of Interests:None declared

Cutaneous Side Effects in 19 Lung Cancer Patients Treated with Gefitinib (Iressa)

2004 ◽  
Vol 66 (6) ◽  
pp. 602-607 ◽  
Author(s):  
Miho UCHIHIRA ◽  
Takahiro EJIMA ◽  
Takao UCHIHIRA ◽  
Jun ARAKI ◽  
Toshiaki KAMEI
Keyword(s):  
Lung Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Cutaneous Side Effects ◽  
Lung Cancer Patients

scholarly journals Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Safa Najafi ◽  
Maryam Ansari ◽  
Vahid Kaveh ◽  
Shahpar Haghighat
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Single Dose ◽  
Side Effects ◽  
Randomized Clinical Trial ◽  
Cancer Patients ◽  
Injection Site Reaction ◽  
Study Groups ◽  
Breast Cancer Patients ◽  
Significant Difference

Abstract Background The objective of this study was to compare the efficacy and side effects of a single dose (Pegfilgrastim or PDL) or repeated six daily injections (Filgrastim or PDG) during chemotherapy courses in breast cancer patients in a non-inferiority clinical trial. Methods In this randomized clinical trial, 80 patients were recruited and allocated randomly to two equal arms. In one group, a single subcutaneous dose of PDL was injected the day after receiving the chemotherapy regimen in each cycle. The second arm received a subcutaneous injection of PDG for six consecutive days in each cycle of treatment. The side effects of GCF treatment and its effect on blood parameters were compared in each cycle and during eight cycles of chemotherapy. Results Hematologic parameters showed no significant differences in any of the treatment courses between the two study groups. The comparison of WBC (p = 0.527), Hgb (p = 0.075), Platelet (p = 0.819), Neutrophil (p = 0.575), Lymphocyte (p = 705) and ANC (p = 0.675) changes during the eight courses of treatment also revealed no statistically significant difference between the two study groups. Side effects including headache, injection site reaction and muscle pain had a lower frequency in patients receiving PDL drugs. Conclusion It seems that PDL is non-inferior in efficacy and also less toxic than PDG. Since PDL can be administered in a single dose and is also less costly, it can be regarded as a cost-effective drug for the treatment of chemotherapy-induced neutropenia. Trial registration IRCT20190504043465N1, May 2019.

scholarly journals Zinc as a complementary treatment for cancer patients: a systematic review

2021 ◽  
Author(s):  
C. Hoppe ◽  
S. Kutschan ◽  
J. Dörfler ◽  
J. Büntzel ◽  
J. Büntzel ◽  
...  
Keyword(s):  
Systematic Review ◽  
Side Effects ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Survival Data ◽  
Positive Impact ◽  
Oral Intake ◽  
Quality Reporting ◽  
Evidenced Based

AbstractZinc is a trace element that plays an important role in the immune system and cell growth. The role of zinc in cancer treatment has been discussed for some time, however without reaching an evidenced-based consensus. Therefore, we aim to critically examine and review existing evidence on the role of zinc during cancer treatment. In January 2019, a systematic search was conducted searching five electronic databases (Embase, Cochrane, PsychINFO, CINAHL and PubMed) to find studies concerning the use, effectiveness and potential harm of zinc therapy on cancer patients. Out of initial 5244 search results, 19 publications concerning 23 studies with 1230 patients were included in this systematic review. The patients treated with zinc were mainly diagnosed with head and neck cancer and underwent chemo-, radio- or concurrent radio-chemotherapy. Interventions included the intake of different amounts of zinc supplements and oral zinc rinses. Outcomes (primary endpoints) investigated were mucositis, xerostomia, dysgeusia, pain, weight, dermatitis and oral intake of nutrients. Secondary endpoints were survival data, quality of life assessments and aspects of fatigue, immune responses and toxicities of zinc. The studies were of moderate quality reporting heterogeneous results. Studies have shown a positive impact on the mucositis after radiotherapy. No protection was seen against mucositis after chemotherapy. There was a trend to reduced loss of taste, less dry mouth and oral pain after zinc substitution. No impact was seen on weight, QoL measurements, fatigue, and survival. The risk of side effects from zinc appears to be relatively small. Zinc could be useful in the prevention of oral toxicities during irradiation. It does not help in chemotherapy-induced side effects.

Sign in / Sign up

Export Citation Format

Share Document